Indivior Plc - ADR
INVVY
Get informed when a big investor buys or sells
+ FollowShare Statistics
| Market cap | $4.78 Billion |
|---|---|
| Enterprise Value | $4.67 Billion |
| Dividend Yield | $0.64 (-) |
| Earnings per Share | $-0.36 |
| Beta | -0.06 |
| Outstanding Shares | 140,988,000 |
Return
| Return on Equity | -175.00% |
|---|---|
| Return on Assets | 21.05% |
| Return on Invested Capital | 81.10% |
Valuation & Multiples
| P/E Ratio | 19.13 |
|---|---|
| PEG | 21.4 |
| Price to Sales | 2.43 |
| Price to Book Ratio | -10.92 |
| Enterprise Value to Revenue | 3.62 |
| Enterprise Value to EBIT | 13.77 |
| Enterprise Value to Net Income | 18 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.44 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Indivior Plc
CEO: Shaun Thaxter Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...
Relevant Senate Committees
This powerful committee controls taxation, trade, and crucial entitlement spending programs like Medicare and Medicaid. Decisions on drug reimbursement, pricing structures, and coverage within these programs directly impact Indivior's revenue and profitability, as would changes in corporate tax policy.
This committee directly regulates the pharmaceutical industry through its oversight of the FDA. Drug approval processes, regulatory changes for prescription medications, and health policy decisions are paramount to Indivior's business, making committee members privy to highly material non-public information.